New Triple-Drug attack on breast cancer shows promise in Late-Stage trial
NCT ID NCT07207070
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial is testing whether adding a new oral drug called JS105 to two standard drugs (dalpiciclib and fulvestrant) can better control advanced breast cancer in people with a PIK3CA gene mutation. The study will enroll 312 adults with HR-positive, HER2-negative breast cancer that has returned or spread. Participants are randomly assigned to receive either the three-drug combo or the two-drug combo alone, and researchers will track how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JS105 (a drug taken by mouth) combined with dalpiciclib and fulvestrant
What this could lead to
If successful, this combination could offer a new treatment option that delays cancer progression in people with a specific genetic mutation (PIK3CA) and advanced breast cancer.
What could go wrong
This is a phase 3 trial, but it's still experimental. The added drug (JS105) may cause more side effects or not improve outcomes. Results may not apply to all breast cancer patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Acadamy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Henan Provincial Cancer Hospital
RECRUITINGZhengzhou, Henan, 450003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact